

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE SIX MONTHS ENDED 30 JUNE 2024

In compliance with the relevant requirements of Shenzhen Stock Exchange, CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”), a subsidiary of CSPC Pharmaceutical Group Limited (the “**Company**”) listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765), has on 16 August 2024 published its unaudited interim report for the six months ended 30 June 2024 (the “**2024 Interim Report**”) on the information disclosure webpage of Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html>. CSPC Innovation’s financial information was prepared in accordance with the China Accounting Standards for Business Enterprises.

Set out in the appendices to this announcement (the “**Appendices**”) is the principal financial data of CSPC Innovation extracted from the 2024 Interim Report in Chinese. In case of any inconsistency between the Chinese version and the English version, the Chinese version shall prevail.

Shareholders and investors are reminded that the financial information of CSPC Innovation in the 2024 Interim Report and in the Appendices are unaudited consolidated financial information of CSPC Innovation for the six months ended 30 June 2024, rather than that of the Company. Investors should exercise caution when dealing in the securities of the Company.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 16 August 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. CAI Dongchen, Mr. ZHANG Cui long, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

APPENDIX I

PRINCIPAL ACCOUNTING INFORMATION AND FINANCIAL INDICATORS

Unit: RMB Yuan

	Current reporting period	Corresponding reporting period of last year		Increase/decrease compared with the corresponding reporting period of last year
		Before adjustment	After adjustment	After adjustment
Revenue (Yuan)	971,860,199.72	1,309,610,573.33	1,344,310,673.33	-27.71%
Net profit attributable to listed company's shareholders (Yuan)	137,027,524.09	400,618,113.97	264,896,828.23	-48.27%
Net profit attributable to listed company's shareholders less non-recurring gains/ losses (Yuan)	134,482,142.06	394,041,608.79	394,041,608.79	-65.87%
Net cash flows from operating activities (Yuan)	-941,443,278.00	346,366,149.89	530,104,008.24	-277.60%
Basic earnings per share (Yuan/share)	0.10	0.35	0.19	-47.37%
Diluted earnings per share (Yuan/share)	0.10	0.35	0.19	-47.37%
Weighted average return on net assets (%)	2.64%	9.21%	5.93%	-3.29%
	End of current reporting period	End of last year		Increase/decrease compared with the end of last year
		Before adjustment	After adjustment	After adjustment
Total assets (Yuan)	5,885,555,800.99	5,632,123,851.51	7,472,208,452.03	-21.23%
Net assets attributable to listed company's shareholders (Yuan)	3,905,217,915.92	5,078,808,635.08	5,280,823,722.20	-26.05%

APPENDIX II

NON-RECURRING GAIN/LOSS ITEMS AND AMOUNTS

Unit: RMB Yuan

Items	Amount	Description
Gain/loss from disposal of non-current assets (including the portion offset with the provision for impairment of assets)	-146,444.23	
Government grants recognised in gain/loss of current period (excluding those closely related to the company's normal operating business, complied with national policies and regulations, granted according to established standards, and continuously affecting the company's gain/loss)	3,701,121.72	
Non-operating income and expenses other than the above items	136,848.61	
Less: Impact of income tax	105,491.93	
Impact of minority interests (after tax)	1,040,652.14	
Total	2,545,382.03	

APPENDIX III

SIGNIFICANT CHANGES IN ASSETS COMPONENTS

Unit: RMB (Yuan)

	End of current reporting period		End of prior year		Increase/ decrease in proportion	Description of significant changes
	Amount	Proportion to total asset	Amount	Proportion to total asset		
Cash and bank balances	1,481,895,498.14	25.18%	3,770,190,307.96	50.46%	-25.28%	Mainly due to settlement of research and development expenses by Megalith Biopharmaceutical, purchase of large-amount deposits by the company, annual equity distribution by the company, repurchase of shares by the company.
Trade receivables	396,891,480.11	6.74%	392,376,024.64	5.25%	1.49%	No significant change.
Contract assets	11,249,999.98	0.19%	11,874,999.98	0.16%	0.03%	No significant change.
Inventories	300,895,981.64	5.11%	224,821,141.86	3.01%	2.10%	No significant change.
Long-term equity investments	263,275,306.94	4.47%	267,068,968.17	3.57%	0.90%	No significant change.
Fixed assets	2,046,066,939.10	34.76%	2,081,907,931.60	27.86%	6.90%	No significant change.
Construction in progress	355,600,390.56	6.04%	228,712,565.18	3.06%	2.98%	No significant change.
Right-of-use assets	1,209,730.89	0.02%	1,612,974.52	0.02%	0.00%	No significant change.
Contract liabilities	20,939,567.16	0.36%	19,803,395.73	0.27%	0.09%	No significant change.
Lease liabilities	425,105.44	0.01%	841,216.40	0.01%	0.00%	No significant change.